Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 7/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | CTSE | P14091 | 2/20 | 0.44 |
| ▸ | PGC | P20142 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29090963 | 0.98 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3ALDH1A1CYP3A4 | |
| SCHEMBL4308696 | 0.84 | GBA1 (0.52) | SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5224978 | 0.83 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL13576618 | 0.81 | KCNH2 (0.53) | ALDH1A1 | |
| SCHEMBL13576643 | 0.81 | KCNH2 (0.53) | ALDH1A1 | |
| Tert-Butyl Formate SCHEMBL27615609 | 0.81 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3ALDH1A1CYP3A4 | |
| SCHEMBL1119467 | 0.79 | ALDH1A1 (0.59) | SLC6A4SLC6A2ALDH1A1CYP3A4 | |
| SCHEMBL894700 | 0.79 | GBA1 (0.66) | SLC6A4ALDH1A1CYP3A4 | |
| SCHEMBL26187362 | 0.78 | GBA1 (0.39) | SLC6A4SLC6A2 | |
| SCHEMBL17296085 | 0.78 | SLC6A2 (0.41) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| CN-101420959-A | Use of 2- (purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives as adenosine A2A receptor agonists | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| CN-101128473-A | Adenosine derivatives having a2a receptor activity | NOVARTIS AG (CH) | 2008-02-20 | — | — | CN | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| CN-1638761-A | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | SLC6A4 1827/4885SLC6A2 3167/4885SLC6A3 2165/4885 |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SLC6A4 1121/4885SLC6A2 1453/4885SLC6A3 372/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | SLC6A4 2321/4885SLC6A2 3439/4885SLC6A3 3067/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | SLC6A4 4608/4885SLC6A2 4844/4885SLC6A3 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.